Cite
Ishibashi K, Haber T, Breuksch I, et al. Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. Oncotarget. 2017;8(33):55230-55245doi: 10.18632/oncotarget.19420.
Ishibashi, K., Haber, T., Breuksch, I., Gebhard, S., Sugino, T., Kubo, H., Hata, J., Koguchi, T., Yabe, M., Kataoka, M., Ogawa, S., Hiraki, H., Yanagida, T., Haga, N., Thüroff, J. W., Prawitt, D., Brenner, W., & Kojima, Y. (2017). Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. Oncotarget, 8(33), 55230-55245. https://doi.org/10.18632/oncotarget.19420
Ishibashi, Kei, et al. "Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade." Oncotarget vol. 8,33 (2017): 55230-55245. doi: https://doi.org/10.18632/oncotarget.19420
Ishibashi K, Haber T, Breuksch I, Gebhard S, Sugino T, Kubo H, Hata J, Koguchi T, Yabe M, Kataoka M, Ogawa S, Hiraki H, Yanagida T, Haga N, Thüroff JW, Prawitt D, Brenner W, Kojima Y. Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. Oncotarget. 2017 Jul 21;8(33):55230-55245. doi: 10.18632/oncotarget.19420. eCollection 2017 Aug 15. PMID: 28903416; PMCID: PMC5589655.
Copy
Download .nbib